Other

Ochsner Clinic Foundation

Louisiana State University and Agricultural & Mechanical College

The Administrators of the Tulane Educational Fund

Ochsner Health System

Thomas Cooper Woods

Hernan Bazan

Corey Keith Goldman

Kevin Yang

Fengchang Hu

Zhide Fang

Yan Lu

Bokkyoo Jun

Song Hong

Brian Wald

Hernan Antonio Bazan

Disclosed are methods of, and assay and kits for, detecting and diagnosing methods of detecting, diagnosing, vulnerable carotid artery disease capable of becoming acutely symptomatic using the levels of Resolvin D1 (RvD1), docosahexaenoic acid (DHA), and arachidonic acid (AA). Also disclosed are methods of treating carotid artery disease and methods of identifying agents for use in the treatment of carotid artery disease.

Methods of detecting, diagnosing, and treating carotid plaque vulnerability

Disclosed are methods of, and assay and kits for, detecting and diagnosing arterial plaque rupture using the expression of miR-222, mi-221 and circ284. Also disclosed are methods of treating arterial plaque rupture and methods of identifying agents for use thin the treatment of arterial plaque rupture.

Methods of detecting, diagnosing, and treating atherosclerotic plaque rupture

The present invention relates to methodology for preventing increased cardiovascular disease in subjects with diabetes mellitus. The methods include the use of compounds to inhibit activation of the extracellular response kinase pathway, activate 5' adenosine monophosphate protein kinase, and inhibit microRNA-221 and microRNA-222 for the purpose of reducing microRNA-221 and -222 levels in the vasculature. Reduction of microRNA-221 and -222 in the vasculature of diabetic patients restores normal levels of intimal thickening and enhances the effectiveness of the standard of care in diabetic subjects.

Use of miR-221 and 222 lowering agents to prevent cardiovascular disease in diabetic subjects

An LED ballast mount preferably includes a housing assembly having sidewalls including a housing LED side wall and a housing opposite side wall. A rechargeable battery is installed in a battery assembly and the battery assembly includes a battery housing mounted to the housing LED side wall. A first LED lamp is mounted on a lower face of the battery housing. A first fluorescent lamp socket mounted on a ballast socket face of the battery housing. A second fluorescent lamp socket mounted on the ballast socket face of the battery housing. A bridge housing including an electronic ballast mounted within the bridge housing. Fluorescent tubes may be mounted in the device.

LED ballast mount

The invention is a method of detecting CAD in a CKD diagnosed human patient or CKD in a CAD diagnosed human patient, or detection of the presence of both CKD and CAD by assaying a plasma or serum sample of a human patient for elevated levels of BMP-4.

Detection of chronic kidney disease patients or coronary artery disease using bone morphogenic protein-4

The invention is a method of detecting CAD in a CKD diagnosed human patient or CKD in a diagnosed CAD patient, or detection the presence of both CDK and CAD by assaying a plasma or serum sample of a human patient for elevated levels of BMP-4.

Growing community of inventors

New Orleans, LA, United States of America

Thomas Cooper Woods